Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer

Cohen, EEW; Licitra, LF; Burtness, B; Fayette, J; Gauler, T; Clement, Paul; Grau, JJ; Del Campo, JM; Mailliez, A; Haddad, RI; Vermorken, JB; Tahara, M; Guigay, J; Geoffrois, L; Merlano, MC; Dupuis, N; Krämer, N; Cong, XJ; Gibson, N; Solca, F; Ehrnrooth, E; Machiels, J-PH

doi:10.1093/annonc/mdx344

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer

Author:

Cohen, EEW

Licitra, LF ; Burtness, B ; Fayette, J ; Gauler, T ; Clement, Paul ; Grau, JJ ; Del Campo, JM ; Mailliez, A ; Haddad, RI ; Vermorken, JB ; Tahara, M ; Guigay, J ; Geoffrois, L ; Merlano, MC ; Dupuis, N ; Krämer, N ; Cong, XJ ; Gibson, N ; Solca, F ; Ehrnrooth, E ; Machiels, J-PH

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, afatinib, methotrexate, HNSCC, biomarker, phase III, EGFR, SQUAMOUS-CELL CARCINOMA, RANDOMIZED PHASE-3 TRIAL, HUMAN-PAPILLOMAVIRUS, LUNG-CANCER, OPEN-LABEL, CETUXIMAB, CHEMOTHERAPY, THERAPY, OVEREXPRESSION, EXTREME, Administration, Intravenous, Administration, Oral, Afatinib, Antimetabolites, Antineoplastic, Biomarkers, Tumor, Biopsy, Carcinoma, Squamous Cell, Disease-Free Survival, Head and Neck Neoplasms, Humans, Methotrexate, Neoplasm Metastasis, Neoplasm Recurrence, Local, Predictive Value of Tests, Quinazolines, Squamous Cell Carcinoma of Head and Neck, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, 3202 Clinical sciences, 3211 Oncology and carcinogenesis

Abstract:

In the phase III LUX-Head & Neck 1 (LUX-H&N1) trial, second-line afatinib significantly improved progression-free survival (PFS) versus methotrexate in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Here, we evaluated association of prespecified biomarkers with efficacy outcomes in LUX-H&N1.